Adaptimmune Therapeutics PLC (ADAP)
0.8246
+0.02
(+3.10%)
USD |
NASDAQ |
Nov 04, 16:00
0.8246
0.00 (0.00%)
After-Hours: 20:00
Adaptimmune Therapeutics Profit Margin (Quarterly): 54.22% for June 30, 2024
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
Date | Value |
---|---|
June 30, 2024 | 54.22% |
March 31, 2024 | -854.2% |
December 31, 2023 | -20.74K% |
September 30, 2023 | -623.0% |
June 30, 2023 | -416.9% |
March 31, 2023 | 2.18% |
December 31, 2022 | -265.2% |
September 30, 2022 | -591.1% |
June 30, 2022 | -803.9% |
March 31, 2022 | -1.41K% |
December 31, 2021 | -2.74K% |
September 30, 2021 | -3.52K% |
June 30, 2021 | -1.26K% |
March 31, 2021 | -8.70K% |
December 31, 2020 | -2.44K% |
September 30, 2020 | -2.97K% |
June 30, 2020 | -5.95K% |
March 31, 2020 | -3.70K% |
December 31, 2019 | -4.03K% |
Date | Value |
---|---|
September 30, 2019 | -16.58K% |
June 30, 2019 | -26.17K% |
March 31, 2019 | |
December 31, 2018 | -2.45K% |
September 30, 2018 | 12.85% |
June 30, 2018 | -485.1% |
March 31, 2018 | -257.2% |
December 31, 2017 | -638.5% |
September 30, 2017 | -3.23% |
June 30, 2017 | -574.1% |
March 31, 2017 | -762.4% |
December 31, 2016 | -180.6% |
September 30, 2016 | -765.5% |
June 30, 2016 | -6.74K% |
March 31, 2016 | -533.8% |
September 30, 2015 | -34.50% |
December 31, 2014 | -70.19% |
September 30, 2014 | -213.0% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
-20.74K%
Minimum
Dec 2023
54.22%
Maximum
Jun 2024
-3.21K%
Average
-1.41K%
Median
Mar 2022
Profit Margin (Quarterly) Benchmarks
Profit Margin (Quarterly) Related Metrics
Return on Equity | -96.68% |
Return on Assets | -24.14% |
Return on Invested Capital | -90.65% |
Operating Margin (Quarterly) | 53.58% |
Return on Net Operating Assets | -60.80% |